In Vitro Evaluation of Smart and pH-Sensitive Chondroitin Sulfate/Sodium Polystyrene Sulfonate Hydrogels for Controlled Drug Delivery.
dissolution
ibuprofen
pH-sensitive hydrogels
swelling
Journal
Gels (Basel, Switzerland)
ISSN: 2310-2861
Titre abrégé: Gels
Pays: Switzerland
ID NLM: 101696925
Informations de publication
Date de publication:
25 Jun 2022
25 Jun 2022
Historique:
received:
31
05
2022
revised:
20
06
2022
accepted:
22
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Ibuprofen is an antipyretic and analgesic drug used for the management of different inflammatory diseases, such as rheumatoid arthritis and osteoarthritis. Due to a short half-life and rapid elimination, multiple doses of ibuprofen are required in a day to maintain pharmacological action for a long duration of time. Due to multiple intakes of ibuprofen, certain severe adverse effects, such as gastric irritation, bleeding, ulcers, and abdominal pain are produced. Therefore, a system is needed which not only prolongs the release of ibuprofen but also overcomes the drug's adverse effects. Hence, the authors have synthesized chondroitin sulfate/sodium polystyrene sulfonate-co-poly(acrylic acid) hydrogels by the free radical polymerization technique for the controlled release of ibuprofen. Sol-gel, porosity, swelling, and drug release studies were performed on the fabricated hydrogel. The pH-responsive behavior of the fabricated hydrogel was determined by both swelling and drug release studies in three different pH values, i.e., pH 1.2, 4.6, and 7.4. Maximum swelling and drug release were observed at pH 7.4, as compared to pH 4.6 and 1.2. Similarly, the structural arrangement and crosslinking of the hydrogel contents were confirmed by Fourier transform infrared spectroscopy (FTIR). Scanning electron microscopy (SEM) evaluated the hard and irregular surface with a few macrospores of the developed hydrogel, which may be correlated with the strong crosslinking of polymers with monomer content. Similarly, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) demonstrated the high thermal stability of the formulated hydrogel, as compared to pure polymers. A decrease in the crystallinity of chondroitin sulfate and sodium polystyrene sulfonate after crosslinking was revealed by powder X-ray diffraction (PXRD). Thus, considering the results, we can demonstrate that a developed polymeric network of hydrogel could be used as a safe, stable, and efficient carrier for the controlled release of ibuprofen.
Identifiants
pubmed: 35877491
pii: gels8070406
doi: 10.3390/gels8070406
pmc: PMC9323728
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Science Council of Taiwan
ID : MOST 110-2320-B-037-014-MY2
Références
Biomaterials. 2002 May;23(9):1955-66
pubmed: 11996036
Int J Biol Macromol. 2015 Sep;80:240-5
pubmed: 26118484
J Pharm Sci. 2005 Oct;94(10):2121-31
pubmed: 16136567
Carbohydr Polym. 2018 Feb 1;181:1169-1179
pubmed: 29253946
Int J Pharm. 2019 Oct 5;569:118557
pubmed: 31377405
Ann Rheum Dis. 2004 Jul;63(7):759-66
pubmed: 15194568
Pak J Pharm Sci. 2020 Jul;33(4):1483-1491
pubmed: 33583778
Drug Dev Ind Pharm. 2019 May;45(5):754-766
pubmed: 30640559
Drug Dev Ind Pharm. 2020 Feb;46(2):272-282
pubmed: 31928342
Mater Sci Eng C Mater Biol Appl. 2016 Nov 1;68:251-257
pubmed: 27524019
Biomaterials. 2003 Nov;24(24):4337-51
pubmed: 12922147
J Control Release. 2006 Oct 27;115(3):266-74
pubmed: 17045356
Int J Biol Macromol. 2018 Dec;120(Pt B):1624-1631
pubmed: 30287359
Life Sci. 2021 Feb 15;267:118931
pubmed: 33359243
Curr Drug Deliv. 2019;16(3):242-253
pubmed: 30360742
Int J Pharm. 2017 Oct 30;532(1):313-317
pubmed: 28888978
J Microencapsul. 2005 Feb;22(1):25-36
pubmed: 16019888
Adv Drug Deliv Rev. 2002 Jan 17;54(1):13-36
pubmed: 11755704
Adv Drug Deliv Rev. 2008 Dec 14;60(15):1638-49
pubmed: 18840488
Pharm Res. 2005 Apr;22(4):584-95
pubmed: 15846466
Orthopedics. 2009 Apr;32(4):
pubmed: 19388612
Pharmaceuticals (Basel). 2021 Mar 08;14(3):
pubmed: 33800248
Colloids Surf B Biointerfaces. 2021 Aug;204:111819
pubmed: 33964528
Eur J Pharm Biopharm. 2007 Feb;65(2):204-14
pubmed: 16996255
Int J Pharm. 2019 Feb 10;556:236-245
pubmed: 30553956
Carbohydr Polym. 2016 Sep 20;149:163-74
pubmed: 27261741
Int J Pharm. 2005 Nov 4;304(1-2):220-30
pubmed: 16182477
Int J Pharm. 2015 Jun 20;487(1-2):110-9
pubmed: 25865571
BMC Chem. 2020 Jan 14;14(1):3
pubmed: 31956861
J Control Release. 2014 Sep 28;190:254-73
pubmed: 24746623
J Pharm Sci. 1983 Oct;72(10):1189-91
pubmed: 6644570
Adv Drug Deliv Rev. 2002 Jan 17;54(1):79-98
pubmed: 11755707
AAPS PharmSciTech. 2009;10(2):670-7
pubmed: 19459052
Nat Mater. 2007 May;6(5):385-92
pubmed: 17435762
Int J Pharm. 2012 Oct 15;436(1-2):602-10
pubmed: 22842627
J Adv Res. 2015 Mar;6(2):105-21
pubmed: 25750745
Ther Deliv. 2019 Nov;10(11):697-717
pubmed: 31789106
J R Soc Med. 2007;100 Suppl 48:2-6
pubmed: 18335846
Carbohydr Polym. 2017 Jun 15;166:183-194
pubmed: 28385222
Indian J Pharm Sci. 2015 Jan-Feb;77(1):83-90
pubmed: 25767322
Eur J Pharm Sci. 2016 Jun 10;88:158-65
pubmed: 26872877
Biomol Eng. 2007 Feb;24(1):131-9
pubmed: 16835016
Pharmaceuticals (Basel). 2021 Apr 09;14(4):
pubmed: 33918921
Pharmaceuticals (Basel). 2021 Mar 25;14(4):
pubmed: 33806015